 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...7374757677787980818283...235236» |
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
I have to leave this decision to the medical oncologist. The genomic profile may occasionally be of great help. No hard data is available regarding prolonged chemo after both FOLFOX and FOLFIRI. (Twitter) - Oct 21, 2022
- oleclumab (MEDI9447) / AstraZeneca, Avastin (bevacizumab) / Roche, Imfinzi (durvalumab) / AstraZeneca
COLUMBIA-1: A Phase Ib/II, Open-Label, Randomized, Multicenter Study of Durvalumab plus Oleclumab in Combination with Chemotherapy and Bevacizumab as First-Line (1L) Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (MSS-mCRC) (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_313;
P1b/2
Conclusions Addition of D + O to FOLFOX + BEV SoC showed a moderate response increase without PFS benefit vs SoC alone. Safety was consistent with known safety profiles.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion chemotherapy(HAIC) + Lenvatinib(len) and tislelizumab(tis) ±transhepatic arterial embolization(TAE) for unresectable hepatocellular carcinoma(uHCC) with portal vein tumor thrombus(PVTT) and high tumor-burden: A multicenter retrospective study (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_241;
Grade 3/4 treatment-related AEs were more frequent in the THLP group than in the HLP group including abdominal pain (34% vs 18%), Nausea (36% vs 22%), and elevated transaminases (10% vs 2%), but there AEs were completely controllable and no treatment-related death happened. Conclusions Additional TAE to triple combination therapy of HAIC, len and tis might improve prognosis compared with triple combination therapy and had accepted toxic effects.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Not sure it really does make any difference and I agree, the small sample makes it challenging. Also, the older studies were all over the map on cis and eto dosing. I am using a lot more FOLFIRINOX now. The FOLFIRINEC trial will hopefully be informative. https://t.co/cCjuJ0SBJ2 (Twitter) - Oct 21, 2022
- | pentoxifylline / Generic mfg.
New P1 trial: Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer (clinicaltrials.gov) - Oct 21, 2022
P1, N=48, Enrolling by invitation, Sponsor: Tanta University
- ||| nadunolimab (CAN04) / Cantargia
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: CAN04CLIN004: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 21, 2022
P1/2, N=40, Active, not recruiting, Sponsor: Cantargia AB
Conclusions Additional TAE to triple combination therapy of HAIC, len and tis might improve prognosis compared with triple combination therapy and had accepted toxic effects. Recruiting --> Active, not recruiting | N=180 --> 40 | Trial completion date: Sep 2024 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Mar 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Circulating tumor DNA: The obj of COBRA ph II/III RCT are To test prospectively if 📌FOLFOX (or CAPOX) can clear ctDNA & 📌⬆️OS in ctDNA(+) pts w/stage IIA colon cancer Pts will be randomized to 📌SOC (more freq Ct scans q6mo) or 📌or ctDNA-informed tx decision Schema below: #CRCTrialsChat (Twitter) - Oct 20, 2022
- | Tibsovo (ivosidenib) / Servier
Journal, PD(L)-1 Biomarker, IO biomarker: An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma. (Pubmed Central) - Oct 20, 2022
Systemic therapy options such as the combination of 5-flurouracil (5-FU) and oxaliplatin (FOLFOX), 5-FU and liposomal irinotecan, and trifluridine/tipiracil (TAS-102) and irinotecan have shown encouraging results...Ivosidenib is an excellent option for IDH1-mutant cholangiocarcinoma that progressed on first-line chemotherapy given its excellent tolerability and median OS benefit. However, a few questions remain unanswered - sequencing of targeted therapies, benefits of combining targeted therapy with systemic chemotherapy or with other treatment modalities, such as immunotherapy and localized therapies.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Real-world evidence: Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer. (Pubmed Central) - Oct 20, 2022
In the 3L cohort, treatment duration was 3.3 months and rwOS was 12.0 months. This large real-world study provides evidence of rwOS in patients with metastatic colorectal cancer receiving cetuximab-based regimens as 2L or 3L treatment.
- | methotrexate IV / Generic mfg., methotrexate / Generic mfg.
Retrospective data, Journal: Feasibility of Delivering High-Dose Methotrexate in Adolescent and Adult All Patients: A Retrospective Study. (Pubmed Central) - Oct 20, 2022
Methods This is a retrospective study of all patients ≥ 15 years of age with newly diagnosed ALL or Lymphoblastic lymphoma (LBL) who were administered HDMTX (part of BFM-90 ALL protocol) at our institute between March 2013 to November 2013.The medical records were reviewed for clinical characteristics, disease-related details, HDMTX dose and cycles administered, leucovorin rescue and toxicities...Conclusion HD-MTX can be safely administered to adolescent and adult ALL patients. A limited methotrexate level monitoring is a safe strategy that can optimize the resources better.
- || methotrexate / Generic mfg.
Review, Journal: Fatal low-dose methotrexate toxicity: a case report and literature review. (Pubmed Central) - Oct 20, 2022
MTX toxicity is rare with low dose, proper dose scheduling, and adherence to the recommended guidelines. It is imperative that physicians considering therapy with low dose MTX for dermatologic indications take into consideration a patient's risk factors for toxicity and monitor appropriately.
- ||| Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
Trial completion date, Metastases: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2022
P3, N=520, Active, not recruiting, Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
It is imperative that physicians considering therapy with low dose MTX for dermatologic indications take into consideration a patient's risk factors for toxicity and monitor appropriately. Trial completion date: Jun 2022 --> Jun 2023
- || cirtuvivint (SM08502) / Biosplice Therap
Enrollment closed, Enrollment change, Trial primary completion date: A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 20, 2022
P1b, N=30, Active, not recruiting, Sponsor: Biosplice Therapeutics, Inc.
Trial completion date: Jun 2022 --> Jun 2023 Recruiting --> Active, not recruiting | N=150 --> 30 | Trial primary completion date: Jul 2026 --> Jul 2024
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
PATTERN OF DISEASE PROGRESSION IN BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH ENCORAFENIB AND CETUXIMAB (EC): A SINGLE INSTITUTION ANALYSIS () - Oct 19, 2022 - Abstract #AIOM2022AIOM_50;
This real life analysis shows that the predominant pattern of PD to EC treatment is a dissociated response and that pts may benefit from subsequent therapy. However, we hypothesize that, due to selective pressure of targeted treatment, part of the disease is still controlled at the time of PD and therefore, stopping targeted therapy and switching to another line of treatment, may cause an hyper progression.
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
THE IMPACT OF SECOND-LINE TREATMENT AFTER FIST-LINE CISPLATIN PLUS GEMCITABINE IN ADVANCED BILIARY TRACT CANCERS: A MONO-INSTITUTIONAL RETROSPECTIVE STUDY () - Oct 19, 2022 - Abstract #AIOM2022AIOM_49;
Our results show that FOLFIRI regimen after a platinum-containing fistline, was independently associated with improved OS. Given that the ABC-06 trial compared FOLFOX to ASC, a randomized trial of FOLFOX vs FOLFIRI as second-line would provide further information.
- Cyramza (ramucirumab) / Eli Lilly
EVOLUTION IN BEYOND FIRST-LINE TREATMENT OF ADVANCED GASTRIC CANCER (AGC) IN THE LAST DECADE: A REAL-WORLD OBSERVATIONAL STUDY FROM MODENA CANCER CENTER () - Oct 19, 2022 - Abstract #AIOM2022AIOM_46;
Patients who undergo beyond 1L therapies have longer OS. Continuum of care and support strategies in AGC are crucial to improve clinical outcomes and survival.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
FLIBER - SERUM CYTOKINE LEVELS AS PREDICTORS OF THE EFFICACY OF AFLIBERCEPT IN COMBINATION WITH FOLFIRI IN METASTATIC COLO-RECTAL CANCER PATIENTS (MCRC) () - Oct 19, 2022 - Abstract #AIOM2022AIOM_45;
Continuum of care and support strategies in AGC are crucial to improve clinical outcomes and survival. FOLFIRI + aflibercept is a safe and effective treatment for mCRC who are resistant to or have progressed after an oxaliplatin-containing regimen.
- Imfinzi (durvalumab) / AstraZeneca, Stivarga (regorafenib) / Bayer
VIVA TRIAL: A RANDOMIZED PHASE II STUDY OF ADJUVANT REGORAFENIB PLUS DURVALUMAB IN STAGE IV COLORECTAL CANCER PATIENTS ACHIEVING THE NO EVIDENCE OF DISEASE STATE () - Oct 19, 2022 - Abstract #AIOM2022AIOM_42;
172 pts are to be accrued to meet the ambitious primary endpoint of a 40% reduction in DFS event rate, corresponding to a median DFS increase from 6 to 10 months. Results (trial in progress): The run-in phase is ongoing on the first 6 pts randomized to the experimental arm using a starting dose of 60 mg/die of Regorafenib (and fixed 1500 mg of Durvalumab), to be escalated after 2 months to 90 mg/die if < 2 patients report serious adverse events.
- Cyramza (ramucirumab) / Eli Lilly
COMPARISON OF PACLITAXEL + RAMUCIRUMAB (PAC/RAM) FOLLOWED BY FOLFIRI VERSUS THE REVERSE SEQUENCE IN UNRESECTABLE OR METASTATIC GASTROESOPHAGEAL AND GASTRIC ADENOCARCINOMA (GA) PATIENTS (PTS) AFTER FRONT-LINE PLATINUM + FLUOROPYRIMIDINE THERAPY () - Oct 19, 2022 - Abstract #AIOM2022AIOM_39;
Results (trial in progress): The run-in phase is ongoing on the first 6 pts randomized to the experimental arm using a starting dose of 60 mg/die of Regorafenib (and fixed 1500 mg of Durvalumab), to be escalated after 2 months to 90 mg/die if < 2 patients report serious adverse events. Our study, even though its retrospective nature and the small number of pts enrolled, suggests similar efficacy of one sequence versus the other, with similar survival outcomes.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
CORRELATION OF EARLY TOXICITY WITH EFFICACY OF SECOND-LINE FOLFIRI-AFLIBERCEPT IN PROSPECTIVELY STRATIFIED, RAS WILD TYPE, ANTI-EGFR RESISTANT, METASTATIC COLORECTAL CANCER PATIENTS – AN INTERIM ANALYSIS OF THE PHASE 2 DISTINCTIVE STUDY – A GISCAD TRIAL () - Oct 19, 2022 - Abstract #AIOM2022AIOM_38;
P=N/A
We found a promising significant correlation between early occurrence of diarrhea and improved PFS. If confirmed in the final analysis, these findings might allow to identify pts with improved benefit from this treatment.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
LABORATORY PARAMETERS PLUS EARLY TOXICITY TO ASSESS PROGNOSTIC GROUPS IN PROSPECTIVELY STRATIFIED, RAS WILD TYPE, ANTI-EGFR RESISTANT, METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH SECOND-LINE FOLFIRI-AFLIBERCEPT IN THE PHASE 2 DISTINCTIVE TRIAL – A GISCAD STUDY () - Oct 19, 2022 - Abstract #AIOM2022AIOM_36;
P=N/A
Our findings showed the prognostic role of the combination of laboratory parameters and early toxicity in RAS wt anti-EGFR resistant mCRC pts receiving FOLFIRI-Aflibercept. These promising results need confirmation in the final analysis of the study and they might represent a useful tool to identify a subgroup of pts who are more likely to benefit from this treatment.
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
IRINOTECAN IS SUPERIOR TO OXALIPLATIN IN KRAS G12C-MUTATED COLORECTAL CANCER AND SHOULD BE PREFERRED IN COMBINATION STRATEGIES WITH KRAS G12C INHIBITORS. A MULTICENTER PROPENSITY SCORE-MATCHED RETROSPECTIVE ANALYSIS (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_33;
The benefit was even more pronounced in the PS-matched analysis, with PS estimation based on age, gender, receipt of bevacizumab, histological grade, performance status, metachronous vs synchronous metastasis, number of metastatic sites, presence of peritoneal metastasis: HR 0.24 (95%CI 0.08-0.71), p 0.01... Irinotecan (i.e. FOLFIRI+/-bev) was significantly superior to oxaliplatin (i.e. FOLFOX+/-bev) in KRASG12C-mutated CRC patients, with a subset of patients (32%) achieving a long-lasting (> 2 years) PFS.
- GUIDELINE APPLICATION IN REAL WORLD: MULTI-INSTITUTIONAL BASED SURVEY OF ADJUVANT AND FIRST-LINE PANCREATIC DUCTAL ADENOCARCINOMA TREATMENT IN ITALY. FIRST ANALYSIS OF THE GARIBALDI TRIAL (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_32;
Data are more representative of Northern Italy. CA19.9 testing should be enhanced; nutritional and psychologic counseling represent an unmet need.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
FOLFOXIRI/BEVACIZUMAB (BEV) COMBINED WITH NIVOLUMAB (NIV) AS FIRST-LINE (1L) THERAPY IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH RAS/BRAF MUTATIONS, REGARDLESS OF MICROSATELLITE STATUS: RESULTS OF PHASE II NIVACOR TRIAL (GOIRC-03-2018) (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_28;
P2
These results show the preliminary efficacy and safety of NIV plus FOLOXIRI/BEV as 1L therapy in mCRC RAS/BRAF mut. The promising activity was observed also in MSS subgroup pts.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Novel Personalized Score Predicts Risk for Postoperative Biliary Leak in Liver Surgery-a Retrospective Database Analysis. (Pubmed Central) - Oct 19, 2022
The presented score is robust and has been validated in an independent patient cohort. Depending on the calculated risk, prevention or early treatment can be initiated to avoid bile leakage and to improve postoperative course.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Journal: Prognostic significance of intrahepatic lymphatic invasion in colorectal liver metastases. (Pubmed Central) - Oct 19, 2022
The presence of intrahepatic lymphatic invasion adversely affected patient's DFS, but not OS in patients with CLMs in the era of FOLFOX/FIRI chemotherapy. FOLFOX/FIRI-based chemotherapy might improve OS, even in patients with positive intrahepatic lymphatic invasion.
- | Clinical Trial,Phase II, Journal: Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Oct 19, 2022
P2
Neoadjuvant FOLFIRINOX followed by concomitant Gemcitabine with radiation was well-tolerated. NCT01897454.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Mitochondrial fitness and cancer risk. (Pubmed Central) - Oct 19, 2022
When analyzed in three independent patient cohorts of pancreatic ductal adenocarcinoma (PDAC), the Mic60-low gene signature was associated with aggressive disease variants, local inflammation, FOLFIRINOX failure and shortened survival, independently of age, gender, or stage. Therefore, the 11-gene Mic60-low signature may provide an easily accessible molecular tool to stratify patient risk in PDAC and potentially other malignancies.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Optimal maintenance treatment strategy following an anti-EGFRbased induction therapy in patients with RAS wild type metastatic colorectal cancer (mCRC): an individual patient data pooled analysis of randomized controlled trials (RCTs) (Auditorium) - Oct 19, 2022 - Abstract #AIOM2022AIOM_103;
This pooled analysis including four random- ized phase II trials showed that a combination mainte- nance schedule with 5-FU/LV and anti-EGFR in RAS wt mCRC is superior in PFS and OS as compared to single- agent maintenance while full treatment break conferred the worst outcomes. The results mirror the available evi- dence on the guideline-recommended maintenance strat- egy after bevacizumab-based first-line therapy.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Avastin (bevacizumab) / Roche, Padcev (enfortumab vedotin) / Seagen, Astellas
EXPLORING TROP2 AND NECTIN4 IMMUNOHISTOCHEMICAL EXPRESSION IN METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE TRIBE2 STUDY () - Oct 19, 2022 - Abstract #AIOM2022AIOM_41;
Overall, 90 (23%), 115 (30%) and 181 (47%) were classified as high, medium and low, respectively. High Trop2 tumours were more frequently BRAF mutated (p=0.005) and rightsided (p=0.03) compared to medium and low ones.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
AN IMMUNE-RELATED GENE EXPRESSION PROFILE PREDICTS THE EFFICACY OF ADDING ATEZOLIZUMAB TO FIRST-LINE FOLFOXIRI/BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A TRANSLATIONAL ANALYSIS OF THE PHASE II RANDOMIZED ATEZOTRIBE STUDY (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_31;
IO score with the predefined cut-point may help to predict benefit from the addition of atezo to firstline FOLFOXIRI/bev in mCRC, even within pMMR tumours. Exploratory IOOPT cut-points should be validated in independent mCRC cohorts.
- Avastin (bevacizumab) / Roche
METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) TREATED WITH UPFRONT CHEMOTHERAPY (CT) + BEVACIZUMAB (BEV) WITHIN TRIBE AND TRIBE2 STUDIES: A FOCUS ON PRIMARY TUMOR RESECTION (PTR) (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_30;
P3
Patients and We conducted a pooled-analysis including pts enrolled in the phase III TRIBE (NCT00719797) and TRIBE-2 (NCT02339116) studies that compared upfront FOLFOXIRI + BEV to FOLFIRI or FOLFOX + BEV, respectively... Baseline PTR was associated with lower incidence of serious gastrointestinal and surgical adverse events during upfront CT plus BEV and impacted positively on prognosis of mCRC pts.
- Vectibix (panitumumab) / Amgen, Takeda
MODIFIED FOLFOXIRI PLUS PANITUMUMAB (MFOLFOXIRI/PAN) VERSUS MFOLFOX6/PAN AS INITIAL TREATMENT OF UNRESECTABLE RAS/BRAF WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC) PATIENTS: RESULTS OF THE PHASE III RANDOMIZED TRIPLETE STUDY BY GONO (Auditorium) - Oct 19, 2022 - Abstract #AIOM2022AIOM_1;
P3
TRIPLETE is a prospective, open label, phase III trial in which untreated patients with unresectable RAS and BRAF wt mCRC were randomized to receive mFOLFOX6/pan (arm A) or mFOLFOXIRI (irinotecan 150 mg/ sqm, oxaliplatin 85 mg/sqm, L-leucovorin 200 mg/sqm, 5-fluoruracil 2400 mg/sqm 48 h infusion)/pan (arm B) up to 12 cycles, followed by 5FU/LV/pan until disease progression... The intensification of the upfront chemotherapy backbone in combination with panitumumab in molecularly selected and mostly (88%) left-sided mCRC patients does not provide any benefit in terms of treatment activity at the price of a non-negligible increase in gastrointestinal toxicity.
- || TTX-030 / AbbVie, Trishula Therap
Trial primary completion date, Metastases: ELTIVATE: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov) - Oct 19, 2022
P1, N=185, Active, not recruiting, Sponsor: Trishula Therapeutics, Inc.
The intensification of the upfront chemotherapy backbone in combination with panitumumab in molecularly selected and mostly (88%) left-sided mCRC patients does not provide any benefit in terms of treatment activity at the price of a non-negligible increase in gastrointestinal toxicity. Trial primary completion date: Sep 2022 --> Dec 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial primary completion date, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 19, 2022
P2, N=39, Active, not recruiting, Sponsor: Al B. Benson, III, MD
Trial primary completion date: Sep 2022 --> Dec 2022 Trial primary completion date: Aug 2022 --> Dec 2022
- | Avastin (bevacizumab) / Roche
Journal: Long-term survivor who underwent surgical resections of repeated peritoneal oligometastases from colon cancer : a rare case report. (Pubmed Central) - Oct 18, 2022
Postoperative chemotherapy comprising 36 courses of mFOLFOX6 with bevacizumab was administered...Invest. 69 : 302-307, August, 2022.
- |||| Clinical: #TumorBoardTuesday This is really innovative - but we haven't been able to use this in our GI cancer patients. We are too concerned about combining oxaliplatin-induced COLD hypersensitivity with scalp cooling 📢Has anyone out there tried scalp cooling with FOLFIRINOX❓ (Twitter) - Oct 18, 2022
- || 5-fluorouracil / Generic mfg.
Review: Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review. (Pubmed Central) - Oct 18, 2022
Among the trials including gemcitabine, 2/9 demonstrated an association with toxicity, whereas 7/9 did not; among those including FOLFIRINOX, one demonstrated associated toxicity whereas the others did not...Furthermore, cut-off values to define sarcopenia in PC patients are not yet uniformly defined. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022337753, identifier CRD42022337753.
- | Retrospective data, Journal: Availability of Antidotes for Management of Acute Toxicity Cases at Emergency Departments in Qassim Hospitals: A Retrospective Study. (Pubmed Central) - Oct 18, 2022
Flagyl, in addition to fluids, was used in the management of 16.7% of cases, N-acetyl cysteine was used for 16.3%, and vitamins K and B6 were used for 14.0% of cases...However, all the hospitals lacked both ethylenediaminetetraacetic acid (EDTA) and a cyanide kit. Methylene blue and leucovorin were available in only one of the studied hospitals.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. (Pubmed Central) - Oct 18, 2022
After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P = .0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Circulating tumor DNA: ✳️We will also learn if escalation approach with FOLFIRINOX can eliminate MRD better than doublets for pts with CtDNA (+) (CohortB) ✳️This cohort will enroll pts with T4 + stage II and N2 + stage III with CtDNA (+) test result that was obtained commercially before study entry ❗️ (Twitter) - Oct 18, 2022
- | IMM-1-104 / Immuneering
New P1/2 trial, Metastases: IMM1104-101: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 18, 2022
P1/2, N=156, Not yet recruiting, Sponsor: Immuneering Corporation
- | oxaliplatin / Generic mfg.
Enrollment open: METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (clinicaltrials.gov) - Oct 18, 2022
P2, N=80, Recruiting, Sponsor: University Hospital, Akershus
FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab. Not yet recruiting --> Recruiting
- || Clinical, Retrospective data, Review, Journal: Different Neoadjuvant Therapies For Locally Advanced Rectal Cancer: A Systematic Review And Network Meta-Analysis. (Pubmed Central) - Oct 18, 2022
FOLFIRINOX followed by capecitabine-based CTRT resulted in better OS than other regimens, including the previous standard, and ranked as the best regimen with a probability of 87%. This NMA confirms that adopting total neoadjuvant therapy improves outcome compared to other preoperative strategies, including FP-based CTRT.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, HEOR: Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. (Pubmed Central) - Oct 16, 2022
This NMA confirms that adopting total neoadjuvant therapy improves outcome compared to other preoperative strategies, including FP-based CTRT. Our analysis suggests that pembrolizumab plus chemotherapy extended life-years and QALYs and is cost effective compared with chemotherapy alone as a first-line treatment for advanced esophageal cancer in the USA given a willingness-to-pay threshold of $150,000 per QALY.
- | Journal: Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. (Pubmed Central) - Oct 16, 2022
Our analysis suggests that pembrolizumab plus chemotherapy extended life-years and QALYs and is cost effective compared with chemotherapy alone as a first-line treatment for advanced esophageal cancer in the USA given a willingness-to-pay threshold of $150,000 per QALY. mFLOT is associated with improved resection rates and survival in comparison to EOX as perioperative therapy in gastric adenocarcinomas in this large real-world cohort, with manageable increase in clinically relevant toxicities such as grade 3 and grade 4 febrile neutropenia and neutropenia.
- | 5-fluorouracil / Generic mfg.
Journal: Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series. (Pubmed Central) - Oct 15, 2022
mFLOT is associated with improved resection rates and survival in comparison to EOX as perioperative therapy in gastric adenocarcinomas in this large real-world cohort, with manageable increase in clinically relevant toxicities such as grade 3 and grade 4 febrile neutropenia and neutropenia. NCR, particularly FOLFIRINOX-based treatment, for BR-PDAC results in higher rates of R0 resection and an increased median DFS and OS, supporting its continued use in this patient group.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Role of Intracellular and Extracellular Annexin A1 in MIA PaCa-2 Spheroids Formation and Drug Sensitivity. (Pubmed Central) - Oct 15, 2022
Additionally, this study has highlighted that the extracellular ANXA1 action is strengthened through the EVs supporting spheroids growth and resistance to drug treatment, mainly affecting tumor progression. Thus, our data interestingly suggest the relevance of ANXA1 as a potential therapeutic PC marker.
- | Journal: FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells. (Pubmed Central) - Oct 15, 2022
This acquired resistance to FOLFOXIRI was overcome with optimized low-dose synergistic drug combinations (ODCs) acting via the Ras-Raf-MEK-ERK pathway. The ODCs inhibited the cell metabolic activity in SW620 and LS174T 3Dcc, respectively by up to 82%.